Useful Consumer Drug Info Implementation May Be Delayed By FDA Guidance
FDA's release of final guidance on consumer medication information could prevent companies from meeting legislatively mandated compliance targets regarding useful written patient information
You may also be interested in...
FDA should convene an expert panel to refine the definition of "usefulness" for written consumer prescription drug information, the American Society of Health-System Pharmacists recommended
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials